Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering
Latest Information Update: 16 Apr 2025
At a glance
- Drugs Inclisiran (Primary)
- Indications Hypercholesterolaemia; Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms SOLVE-LDL-C
- 11 Apr 2025 Status changed from not yet recruiting to recruiting.
- 17 Mar 2025 Planned initiation date changed from 1 Mar 2025 to 30 Mar 2025.
- 14 Mar 2025 New trial record